Wanbury Limited (BOM:524212)

Market Cap	8.88B +14.7%
Revenue (ttm)	6.58B +16.1%
Net Income	646.86M +47.3%
EPS	19.23 +49.9%
Shares Out	34.89M
PE Ratio	13.24
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,031
Average Volume	18,933
Open	255.25
Previous Close	259.30
Day's Range	255.25 - 279.70
52-Week Range	155.00 - 330.00
Beta	-0.26
RSI	64.92
Earnings Date	Feb 5, 2026

About Wanbury

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its n...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 1,382
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524212

Financial Performance

In fiscal year 2025, Wanbury's revenue was 6.00 billion, an increase of 3.88% compared to the previous year's 5.78 billion. Earnings were 305.30 million, a decrease of -45.44%.